Are gastric metastases of renal cell carcinoma really rare? A case report and systematic review of the literature

Thomas Prudhomme a,b,*, Charlotte Maulat a, Guillaume Péré a, Fatima-Zohra Mokrane c, Michel Soulié b, Fabrice Muscari a

a Department of Digestive Surgery, Toulouse University Hospital, 31059, Toulouse, France
b Department of Urology and Kidney Transplantation, Toulouse University Hospital, 31059, Toulouse, France
c Department of Radiology, Toulouse University Hospital, 31059, Toulouse, France

A R T I C L E   I N F O

Article history:
Received 14 March 2021
Received in revised form 30 March 2021
Accepted 31 March 2021
Available online 6 April 2021

Keywords:
Renal cell carcinoma
Gastric metastases
Surgical treatment
Systemic treatment
Metastatic recurrence
Case report

A B S T R A C T

INTRODUCTION: Renal cell carcinoma (RCC) represents above 3% of all cancers. At diagnosis, above 25% of patients with RCC present an advanced disease. Gastric metastasis of RCC is associated with poor outcome. We report the case of a patient treated for a gastric metastasis of RCC and we conducted a systematic review of the literature to report all published cases of RCC patients with gastric metastasis.

CASE PRESENTATION: In December 2010, a 61-year-old man was treated by open partial nephrectomy for a localized right clear cell RCC. In September 2018, a metachronous gastric metastasis was found on CT scan. The lesion was located on the lesser curvature of the stomach, measuring 4.5 cm long axis. No other secondary lesions were identified. A laparoscopic wedge resection, converted to laparotomy was performed. Two years later, in September 2020, a CT scan was performed, revealing a 17 mm adenopathy behind the hepatic hilum and a surgical management was performed, including a lymph node dissection of the hepatic hilum and the hepatic artery. Actually, he remains healthy.

CLINICAL DISCUSSION AND CONCLUSION: Our systematic review suggests that solitary gastric metastasis of RCC are scarce. In comparison of patients with multiple metastatic sites, the median survival of patients with solitary gastric metastasis is longer.

© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Renal cell carcinoma (RCC) represents above 3% of all cancers, with the highest incidence occurring in Western countries [1]. At diagnosis, above 25% of patients with RCC present an advanced disease, including locally invasive or metastatic cancer [2,3]. The mean survival time of patient with metastatic RCC is approximately 13 months [1].

The most common metastatic RCC sites are the lung and bone (up to 60% and 40% of patients with metastases) [4]. However, unusual sites of metastasis are characteristics of RCC and any organ site can be involved, including the thyroid, pancreas, skeletal muscle and skin.

Gastric metastasis of RCC has been described [5–39] and it is associated with poor outcome, with only a third of patients being alive after one year [23]. Usually, gastric metastases are asymptomatic, single and located in the gastric body or fundus [23,33].

Thus, these metastases are diagnosed on routine CT scans as part of the monitoring of RCC after local treatment. Gastrointestinal bleeding and anemia are the most common presentations of symptomatic gastric metastasis [23,33].

We herein report the case of a patient, who underwent a wedge resection for a gastric metastasis of RCC, which is healthy at 2-years of follow-up. Furthermore, we conducted a systematic review of the literature to report all published cases of RCC patients with gastric metastasis.

2. Case report

In December 2010, a 61-year-old man was referred to our academic center for the management of a localized right clear cell RCC, without synchronous metastases. It was an upper polar lesion, measuring 2.5 cm long axis, essentially exophytic, posterior, entirely above the polar lines, without vascular contact, classified 5p RENAL score.

An open right partial nephrectomy was performed by an experienced surgeon and histological results highlighted a 2.5 cm clear cell RCC. Furhman grade III, classified pT3aN0R0 due to the extension to perinephric tissues, but not beyond Gerota Fascia.

* Corresponding author at: Department of Urology and Kidney Transplantation, TSA 50032 Rangueil Hospital, 31059, Toulouse Cedex 9, France.
E-mail address: prudhomme.t@chu-toulouse.fr (T. Prudhomme).

https://doi.org/10.1016/j.ijscr.2021.105867
2210-2612/© 2021 Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
According to EAU (European Association of Urology) guidelines, a surveillance has been validated including semi-annual monitoring by CT scan in the 1st year, then annual monitoring by CT scan in the following 2 years and every 2 years thereafter.

In Mars 2012, a localized homolateral recurrence has been highlighted at CT scan. It was a lower polar lesion, measuring 4.3 cm long axis, essentially endophytic, anterior, close to the collecting system, with polar line crosses and venous contact, classified 9 ah RENAL score, Supplemental Fig. 1. There was no evidence of metastasis on this CT scan.

An open right radical nephrectomy was performed and histological examination reported a 3.5 cm clear cell RCC, Furhman grade III, classified pT3aN0R0 due to the extension to the renal sinus fat.

Fig. 1. PRISMA flow diagram.
According to EAU guidelines [40], a surveillance has been validated.

In September 2018, a metachronous gastric metastasis was found on CT scan. The lesion was located on the lesser curvature of the stomach, measuring 4.5 cm long axis. No other secondary lesions were identified, Supplemental Fig. 2. The patient had no digestive symptoms, no hematemesis, no melena.

A surgical procedure has been validated: a laparoscopic wedge resection, converted to laparotomy has been performed.

Histological examination reported a proliferation of atypical cells containing round clear nuclei and irregularly shaped nuclei with prominent nucleoli using hematoxylin-eosin staining. Immunostaining revealed negativity for all epithelial markers (CK7, CK20) and positivity for proximal tubular epithelial markers (CD10, Vimentine). These characteristics led to the conclusion of gastric metastasis of a clear cell RCC with 30% sarcomatoid contingent, with negative resection margins.

The patient had an uneventful postoperative course and was discharged on the 8th day. Two years later, in September 2020, a CT scan was performed, revealing a 17 mm adenopathy behind the hepatic hilum and a surgical management was performed, by an experienced surgeon, including a lymph node dissection of the hepatic hilum and the hepatic artery. Histological examination reported a node metastasis of the clear cell RCC in hepatic artery lymph node dissection. Actually, he remains healthy.

This case has been reported in line with the SCARE 2020 criteria [41].

3. Systematic review

Literature about gastric metastasis of RCC was realized using electronic database Medline via PubMed (1950–2018).

Key terms used included “renal cell carcinoma,” “stomach metastasis,” and “gastric metastasis” (Fig. 1). References in the identified articles were used to identify more relevant studies.

RCC with solitary gastric metastasis cases (n = 11) are summarized in Table 1.

The median patients age (IQR) was 68.0 (62.8–73.3) years, of whom 82% were men. The most frequent locations of metastasis were the middle body of the stomach (45%), followed by the upper body of the stomach (36%) and the lower body of the stomach (18%). The median time (IQR) between the diagnosis of RCC and metachronous gastric metastasis was 8.5 (3.8–19.3) years. 1 patient presented RCC with synchronous gastric metastasis. A surgical treatment of the metastasis was performed in 64% of the patients and an endoscopic treatment in 27% of the cases. Endoscopic treatment was a submucosal resection without positive surgical margins. 1 patient received a palliative chemotherapy. Median patient survival (IQR), after treatment, was 9 months (3.4–15.8).

RCC with multiple or unspecified metastatic sites (including stomach) cases (n = 31) are summarized in Table 2.

At RCC gastric metastasis diagnosis, 73% of the patients presented multiple metastatic sites, mainly lungs and bones. The median patients age (IQR) was 66.0 (60.0–69.0) years, of whom 74% were men. The median time (IQR) between the diagnosis of RCC and metachronous gastric metastasis was 5.0 (2.0–9.5) years. 3 patients presented RCC with synchronous gastric metastasis. 35% of the patients had a surgical treatment, 16% an endoscopic treatment, 23% a systemic therapy and 26% a palliative treatment. Endoscopic treatment was mucosal and submucosal resection without positive surgical margins. Median patient survival (IQR), after treatment, was 6 months (2.5–24.0).

4. Discussion

Renal cell carcinoma is the most common solid lesion within the kidney and accounts approximately 90% of all kidney malignancies [1]. It comprises different RCC subtypes with specific histopathological characteristics [42]. Clear cell RCC is the most common histopathological entities of RCC [40] and clear cell RCC has worse prognosis compared to other histopathological entities [43,44], even after stratification for stage and grade [45].

Indeed, clear cell RCC has an abundant blood supply and can metastasize to several organs [46]. Metastasis routes include hematogenous, lymphogenous, renal capsule, renal pelvis and ureteric routes [37], which explains the wide variety of organs that can be RCC metastatic sites.

Currently, EAU guidelines [40] and French ccaFU (comité de cancérologie de l’Association Française d’Urologie) guidelines [47] on management of kidney cancer recommends using MSKCC and IMDB prognostic models to establish the prognosis of patients with metastatic RCC, in order to select the appropriate therapy. Thus, EAU [40] and French ccaFU guidelines [47] recommend offering surgical treatment, when technically feasible, of metastases in patients with oligo-metastatic RCC, in order to defer the initiation of systemic therapy.

Our systematic review suggests that solitary gastric metastasis of RCC are scarce. Herein, we report the 12th case of solitary gastric metastasis, discovered 6 years after local treatment of RCC. For the
Table 2  
Summary of RCC with gastric and multiple or unspecified metastasis site cases reported in the literature.

| Author                     | Year | Age | Sex | Location  | Interval (years) | Treatment                        | Additional metastases | Outcomes                      |
|----------------------------|------|-----|-----|-----------|------------------|----------------------------------|------------------------|--------------------------------|
| Ibañez Olczo et al. [6]    | 1989 | 60  | M   | M         | 1.8              | Palliative treatment              | Lung, brain            | Died 33 days after operation  |
| Marquez et al. [7]         | 1992 | 70  | M   | M         | 0.1              | Palliative treatment              | Pleura                 | Died 4 weeks                  |
| Dourou et al. [8]          | 1992 | 66  | M   | U         | 12               | Interferon treatment              | Lung, adrenal          | ND                             |
| Herrera Puerto et al. [9]  | 1993 | 63  | M   | L         | 0.1              | No surgical treatment             | Palliative treatment   | Lung                           |
| Boruchowicz et al. [10]    | 1995 | 48  | M   | U         | 1                | Chemotherapy                      | Lung, liver, esophagus | ND                             |
| Blake et al. [11]          | 1995 | 63  | M   | M         | 6                | Palliative embolization           | Lung                   | No complications at 5 months  |
| Mascarenhas et al. [14]    | 2001 | 66  | M   | U         | 7                | Partial gastrectomy               | Lung, pleura           | 3-year survival                |
| Kok Wee et al. [15]        | 2004 | 60  | M   | M         | 20               | Total gastrectomy                 | Lung, liver, pancreas  | ND                             |
| Kobayashi et al. [16]      | 2004 | 68  | M   | L         | 11               | Total gastrectomy                 | Palliative treatment   | Died at 2 years                |
| Suarez Fonseca et al. [17] | 2004 | 61  | F   | M         | 4                | Chemotherapy                      | Lung                   | 6-month survival               |
| Lamb et al. [18]           | 2005 | 69  | F   | M         | 3                | Palliative embolization           | Lung, thyroid          | Died 23 month after therapy   |
| Riviezzo et al. [19]       | 2006 | 68  | M   | U         | 11               | Total gastrectomy                 | Lung, brain, pancreas  | Died 24 month after therapy   |
| Portanova et al. [20]      | 2006 | 67  | F   | M         | 5                | Total gastrectomy                 | Pancreas               | ND                             |
| Pezzi et al. [22]          | 2007 | 78  | M   | U         | 5                | Endoscopic treatment              | ND                     | Died 6 months after therapy    |
| Pollheimer et al. [23]     | 2008 | 69  | M   | M         | 4                | Tamoxifen                         | Lung, bone, adrenal    | Died 19 months after therapy   |
| Pollheimer et al. [23]     | 2008 | 77  | M   | L         | 6                | No surgical treatment             | Lung                   | Died 4 months after therapy    |
| Pollheimer et al. [23]     | 2008 | 83  | F   | L         | 2                | Interferon treatment              | Lung, liver, pancreas  | Died 5 months after therapy    |
| Pollheimer et al. [23]     | 2008 | 65  | F   | ND        | 13               | No surgical treatment             | Lung, brain            | Died 3 months after therapy    |
| Pollheimer et al. [23]     | 2008 | 69  | M   | M         | 9                | Partial gastrectomy               | Lung, bone            | 2-year survival                |
| Yamamoto et al. [24]       | 2009 | 74  | M   | M         | 5                | Partial gastrectomy               | Brain                  | Died 1 month after therapy     |
| Kibria et al. [25]         | 2009 | 53  | M   | U         | 0                | Palliative treatment              | Lung, bone            | Died 2 months after therapy    |
| Maeda et al. [26]          | 2009 | 49  | M   | M         | 2                | Partial gastrectomy               | Lung                   | Died 15 months after therapy   |
| Tiwari et al. [28]         | 2010 | 58  | F   | L         | 0                | Subtotal gastrectomy              | Lung                   | Died 2 months after therapy    |
| Eslick et al. [39]         | 2010 | 65  | M   | M         | 9                | Endoscopic treatment              | Bone                   | Died 6 months after therapy    |
| Sakurai et al. [30]        | 2014 | 61  | M   | M         | 2                | Partial gastrectomy               | Lung, bone            | Died 4 months after therapy    |
| Ikari et al. [31]          | 2014 | 64  | M   | M         | 12               | Endoscopic treatment              | Pancreas               | 30-month survival after therapy|
| Sogabe et al. [35]         | 2016 | 53  | M   | L         | 2                | Sunitinib                         | Mediastinal Lymph Node| 4-year survival after therapy  |
| Arakawa et al. [37]        | 2018 | 80  | F   | M         | 0                | Sunitinib                         | Lung, liver           | ND                             |
| Kinoshita et al. [47]      | 2019 | 60  | M   | M         | 3                | No surgical treatment             | Partial gastrectomy   | Gallbladder                     |
| Bernshtein et al. [48]     | 2019 | 68  | M   | ND        |                | Endoscopic treatment              | ND                     | 9-months survival               |
| Orosz et al. [49]          | 2020 | 73  | M   | U         | ND               | Endoscopic treatment              | Brain                  | ND                             |

Location (L: Lower body of the stomach; M: Middle body of the stomach; U: Upper body of the stomach).

11th cases reported in the literature, the median age of the patients was 68.0 years, of whom 82% were men. The most frequent locations of metastasis were the middle body of the stomach (45%), followed by the upper body of the stomach (36%) and the lower body of the stomach (18%). The median time between diagnosis of RCC and metachronous gastric metastasis was 8.5 years. A surgical treatment of the metastasis was performed in 64% of the patients and an endoscopic treatment in 27% of the cases. Thus, in case of solitary gastric metastasis of RCC, endoscopic or surgical treatment of the metastasis, allows to delay the initiation of systemic treatment, with median patient survival of 9 months after treatment. Our case has a similar age. The location of the metastasis was the middle body of the stomach. The median time between diagnosis of RCC and metachronous gastric metastasis was 6 years, lower than median time reported by the 11th cases. Two years after gastric metastasis surgical treatment, a hepatic hilum adenopathy recurrence occurred, treated by surgery and our median patient survival was higher (26 months versus 9 months).

However, in case of multiple metastatic sites, the stomach is a frequent localization of metastases. Thus, at gastric metastases diagnosis, 80% of patients presented multiple metastatic sites, mainly lungs and bones. The median time between RCC diagnosis and metachronous gastric metastasis diagnosis was shorter in case of multiple metastatic sites (5.0 years versus 8.5 years in case of solitary gastric metastasis).

Surgical treatment, when it is feasible remains the best therapeutic option for a solitary gastric metastasis, resulting in significant survival prolongation in eligible patients. Indeed, median
patient survival was higher after surgical treatment of gastric metastasis (9 months (3.4–15.8) versus 6 months (2.5–24.0) in case of solitary and multiple metastatic sites).

However, after surgical treatment of solitary gastric metastases, the risk of metastatic recurrence is significant. Among the 11 cases of solitary gastric metastasis reported in the literature, 3 patients presented a metastasis recurrence. Our case presented a hepatic hilum adenopathy recurrence, treated by surgery, two years after gastric metastasis surgical treatment.

5. Conclusion

Our systematic review suggests that solitary gastric metastasis of RCC are scarce. In comparison of patients with multiple metastatic sites, the median survival of patients with solitary gastric metastasis is longer. When it is feasible, surgical or endoscopic treatment of the solitary gastric metastasis should be performed, whenever the patient is fit for surgery, in order to delay the initiation of systemic treatment. Nevertheless, the risk of metastatic recurrence is significant and must be taken into consideration in the therapeutic strategy.

Declaration of Competing Interest

None.

Funding

None.

Ethical approval

According to French legislation, retrospective studies are not subject to an ethics committee.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author's contribution

Dr. Thomas Prudhomme: Data collection, Data analysis, Manuscript writing

Dr. Charlotte Mault: Data collection, Data analysis

Dr. Guillaume Père: Data collection, Data analysis

Dr. Fatima-Zohra Morkane: Data collection, Data analysis

Pr. Michel Soulé: Data collection, Data analysis

Pr. Fabrice Muscari: Data collection, Data analysis, Manuscript writing.

Registration of research studies

Not applicable.

Guarantor

Thomas Prudhomme.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi: https://doi.org/10.1016/j.jscr.2021.105867.

References

[1] J. Ferlay, M. Colombo, I. Soerjomataram, T. Dyba, G. Randi, M. Bettio, A. Gavin, O. Divser, F. Bray. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018, Eur. J. Cancer 103 (2018) 356–387.
[2] B.L. Rini, S.C. Campbell, B. Escudier, Renal cell carcinoma, Lancet 373 (2009) 1119–1122.
[3] H.T. Cohen, F.J. McGovern, Renal-cell carcinoma, N. Engl. J. Med. 355 (2003) 2477–2490.
[4] M. Bianchi, M. Sun, C. Jeldres, S.F. Shariat, Q.D. Trinh, A. Brigandi, Z. Tian, J. Schmitges, M. Graeven, P. Perrozzi, M. Menon, F. Montorsi, P.J. Karakiewicz, Distribution of metastatic sites in renal cell carcinoma: a population-based analysis, Ann. Oncol. 23 (2012) 973–980.
[5] W.G. Sullivan, E.B. Cabot, R.E. Donohue, Metastatic renal cell carcinoma to stomach, Urology 15 (1980) 375–378.
[6] J. Ilanex Pezo, C.E. Jimenez Lopez, J.A. Otoe Revuelta, F. Cobo Huici, M.J. Sara Ongay, M. Garcia Carasusu, R.M. Guarch Troyas, Gastric metastasis of renal adenocarcinoma. Presentation of a case and review of the literature, Rev. Esp. Enferm. Apar. Dig. 76 (1988) 259–261.
[7] J.L. Marquez, J.M. Herrera, J.M. Herrera, M. Caballero, I. Navarrea, J.M. Pascasio, J.J. Pimentel, M. Pahon, P. Vega, A. Soria, Gastric metastasis of renal cell adenocarcinoma, Rev. Esp. Enferm. Dig. 81 (1992) 129–130.
[8] E. Durous, S. Isaac, D. Dubreuil, G. Braillon, S. Bonvoisin, L. Desco, Late gastric metastasis of cancer of the kidney, Presse Med. 21 (1992) 996.
[9] J. Herrera Puerto, M. Caballero Gomez, J.L. Marquez Galan, C. Dominguez Bravo, J.L. Soler Fernandez, J. Cabello Padiel, J. Murillo Mirat, S. Auzar Aydillo, Metastatic hypernephroma of the stomach, Arch. Esp. Urol. 46 (1993) 729–731.
[10] A. Boruchowicz, P. Desreuxaux, V. Mannoury, J.F. Colombel, Dysphagia revealing esophageal and gastric metastases of renal carcinoma, Am. J. Gastroenterol. 90 (1995) 2263–2264.
[11] M.A. Blake, A. Owens, D.P. Donohue, D.P. MacErlane, Embolotherapy for massive upper gastrointestinal haemorrhage secondary to metastatic renal cell carcinoma: report of three cases, Gut 37 (1995) 835–837.
[12] T. Ondori, Y. Tsuboi, K. Katoh, Y. Yamada, K. Morita, A. Ohara, M. Kuroiwa, H. Sakamoto, T. Sakata, A solitary hermogenous metastasis to the gastric wall from renal cell carcinoma four years after radical nephrectomy, J. Clin. Gastroenterol. 26 (1998) 153–154.
[13] M. Picchio, A. Paioletti, E. Santini, S. Iacoponi, M. Cordahi, Gastric metastasis from renal cell carcinoma fourteen years after radical nephrectomy, Acta Chir. Belg. 100 (2000) 228–230.
[14] B. Mascarenhas, B. Konyet, J.T. Rubin, Recurrent metastatic renal cell carcinoma presenting as a bleeding gastric ulcer after a complete response to high-dose interleukin-2 treatment, Urology 57 (2001) 118.
[15] L. Kok Wee, R.Y. Shyu, L.F. Shou, T.Y. Hsieh, J.C. Yan, P.J. Chen, Metastatic renal cell cancer, Gastrointest. Endosc. 60 (2004) 265.
[16] O. Kobayashi, H. Murakami, T. Yoshida, H. Cho, T. Yoshikawa, A. Tsuburaya, M. Sairenji, H. Motohashi, Y. Sugiyama, Y. Kameda, Clinical diagnosis of metastatic gastric tumors: clinicopathologic findings and prognosis of nine patients in a single cancer center, World J. Surg. 28 (2004) 548–551.
[17] C. Suarez Fonseca, J. Carballido Rodriguez, Y. Gonzalez Lama, I. Sola Galarza, G. Rodriguez Reina, C. Salas Antón, Gastric metastasis from renal cell carcinoma. Pathogenetical hypothesis and literature revision, Actas Urol. Esp. 28 (2004) 472–476.
[18] G.W. Lamb, J. Moss, R. Edwards, M. Atchison, Case report: octreotide as an adjunct to embolisation in the management of recurrent bleeding upper gastrointestinal metastases from primary renal cell cancer, Int. Urol. Nephrol. 37 (2005) 691–693.
[19] C. Rivello, I. Tanini, C. Cipriani, P. Pantaleo, C. Nozzoli, A. Poma, V. Riccardo, A. Valeri, Unusual gastric and pancreatic metastatic renal cell carcinoma presentation 10 years after surgery and immunotherapy: a case report and a review of literature, World J. Gastroenterol. 12 (2006) 5234–5236.
[20] M. Portanova, A. Yabar, E. Lombardi, F. Vargas, V. Menu, R. Carbajal, N. Palacios, J. Orrego, Comitant gastric and pancreatic metastasis from renal cell carcinoma: case study, Rev. Gastroenterol. Peru 26 (2006) 84–88.
[21] R.F. Saidi, S.G. Remine, Isolated gastric metastasis from renal cell carcinoma 10 years after radical nephrectomy, J. Gastroenterol. Hepatol. 22 (2007) 143–144.
[22] A. Pezzoli, V. Matarrese, S. Bocca, L. Simone, S. Gullini, Gastrointestinal bleeding from gastric metastasis of renal cell carcinoma, treated by endoscopic polypectomy, Endoscopy 39 (Suppl. 1) (2007) E52.
[23] M.J. Pollheimer, T.A. Hinterleitner, V.S. Pollheimer, A. Schlemmer, C. Langner, Renal cell carcinoma metastatic to the stomach: single-centre experience and literature review, BJU Int. 102 (2008) 315–319.
[24] D. Yamamoto, Y. Hamada, S. Okazaki, K. Kawakami, S. Kanazaki, C. Yamamoto, M. Yamamoto, Metastatic gastric tumor from renal cell carcinoma, Gastric Cancer 12 (2009) 170–173.
This article is published Open Access at scienecdirect.com. It is distributed under the iJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.